Meeting
2018 ASCO Annual Meeting
Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma.
Authors
Chunmeng Wang
Bio-therapeutic Department, Molecule & Immunology Department, Chinese PLA General Hospital, Beijing, China
Chunmeng Wang , Yang Liu , Jing Nie , Lianjun Shen , Qingming Yang , WeiDong Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02961101 and NCT03250962
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7537)
DOI
10.1200/JCO.2018.36.15_suppl.7537
Abstract #
7537
Poster Bd #
174
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
First Author: David Lavie
Poster
2020 ASCO Virtual Scientific Program
Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.
First Author: Yuqin Song
Poster
2018 ASCO Annual Meeting
Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.
First Author: Wenying Zhang
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin